CytoBay offers a patented Liquid ICC platform that combines morphology and tumor marker expression onto a single cytology slide. This technology enables pathologists to perform accurate evaluations on patient liquid samples using existing ICC CPT billing codes. The platform utilizes a porous membrane to maintain cell integrity during reagent changes for reliable diagnostic testing.
Funding
Funding not disclosed
Founders
Product
Problem
Pathologists require accurate evaluations of patient liquid samples, but traditional methods can lead to cell loss during reagent processing. This loss can compromise the integrity of morphology and tumor marker expression data, impacting diagnostic precision.
Solution
CytoBay offers a patented Liquid ICC platform designed to enhance the accuracy of liquid sample analysis for pathologists. The platform integrates morphology and tumor marker expression onto a single cytology slide, a novel approach that preserves cellular integrity throughout the diagnostic workflow. By employing a porous membrane for reagent changes, the system minimizes cell loss, ensuring that critical diagnostic information is retained. This technology is designed to align with existing ICC CPT billing codes, facilitating its adoption within standard clinical practice.
Target Audience
The primary customers are pathologists and diagnostic laboratories seeking to improve the accuracy and efficiency of liquid sample analysis.
Features
- Patented Liquid ICC platform for simultaneous morphology and tumor marker analysis on a single cytology slide.
- Utilizes a porous membrane during reagent changes to prevent cell loss and maintain sample integrity.
- Enables accurate evaluations of patient liquid samples by preserving cellular material.
- Compatible with existing ICC CPT billing codes for streamlined clinical integration.